Your browser doesn't support javascript.
loading
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot, S; George, E C; Pozniak, A; White, E; Schwimmer, C; Jessen, H; Johnson, M; Dunn, D; Perno, C F; Clotet, B; Plettenberg, A; Blaxhult, A; Palmisano, L; Wittkop, L; Calvez, V; Marcelin, A G; Raffi, F.
Afiliación
  • Lambert-Niclot S; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, UMR_S 1136, AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, F-75013, France sidonie.lambert@psl.aphp.fr.
  • George EC; MRC Clinical Trials Unit at UCL, London, UK.
  • Pozniak A; Chelsea and Westminster Hospital, London, UK.
  • White E; MRC Clinical Trials Unit at UCL, London, UK.
  • Schwimmer C; INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France.
  • Jessen H; Gemeinschaftspraxis Jessen-Stein, Berlin, Germany.
  • Johnson M; Department of HIV Medicine, Royal Free Hospital, London, UK.
  • Dunn D; MRC Clinical Trials Unit at UCL, London, UK.
  • Perno CF; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Clotet B; HIV Unit and Retrovirology Laboratory 'Irsicaixa' Foundation, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain.
  • Plettenberg A; Ifi-institut, an der Asklepios-Klinik St Georg, Hamburg, Germany.
  • Blaxhult A; Department of Infectious Diseases, Venhaelsan-Sodersjukhuset, Stockholm, Sweden.
  • Palmisano L; Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Wittkop L; INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale, Bordeaux, France Université de Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France.
  • Calvez V; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, UMR_S 1136, AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, F-75013, France.
  • Marcelin AG; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, UMR_S 1136, AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, F-75013, France.
  • Raffi F; CMIT, 46 Rue Henri Huchard, 75018 Paris, France.
J Antimicrob Chemother ; 71(4): 1056-62, 2016 Apr.
Article en En | MEDLINE | ID: mdl-26702926
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Carga Viral / Terapia Antirretroviral Altamente Activa / Farmacorresistencia Viral Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Antimicrob Chemother Año: 2016 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Carga Viral / Terapia Antirretroviral Altamente Activa / Farmacorresistencia Viral Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Antimicrob Chemother Año: 2016 Tipo del documento: Article País de afiliación: Francia